Patricia Loranca-Moreno
Mexico City, Gustavo A. Madero, 07300, Mexico
NCT Number: NCT05372224
Denosumab is a monoclonal antibody against RANKL ligand, which is used as an alternative treatment for osteoporosis in patients who have a poor response to first-line antiresorptive therapy. However, discontinuation of denosumab produces a rapid increase in bone turnover, bone loss and potentially increased risk of multiple vertebral fractures.
Looking for future studies?
Notify Me45 year–89 year
Female
Interventional
Not applicable
Mexico City, Gustavo A. Madero, 07300, Mexico
76 postmenopausal women from the climacteric clinic of the regional hospital "1o de Octubre" of the Institute of Security and Social Services for State Workers (ISSSTE) were firstly considered, of which 23 presented elimination criteria and only 55 who had received denosumab therapy for an average of 2.5 years without a significant improvement in hip and lumbar spine T-scores were enrolled. First, a general medical evaluation was performed. Serum levels of vitamin D were analysed to find the prevalence of hypovitaminosis D. A bone mineral density test was done to calculate hip and lumbar spine T-scores. Then, vitamin D was administrated daily for one year at a dose of 4,000 IU and the studies were repeated after one year. Statistical analysis was performed using PAST 3.0 and GraphPad Prism 8.4.3. software. The arithmetic median (µ) and standard deviation (S.D.) were calculated using Excel-Word. Graphics were constructed with GraphPad Prism 8.4.3 and tables with Excel Word. Categorical variables were analysed with chi-squared or Fisher exact test depending on the number of participants in each cell. Normality was determined using the Shapiro-Wilk test. To compare two paired samples, the Wilcoxon signed-rank test was utilized. The assigned α value for this study was <0.05. In all cases, if a Montecarlo permutation was available, the exact p-value was taken instead of the raw p-value.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
4000 IU were administrated once a day for 3 months.
Other names: Histofil®
Time frame: 12 months
It refers to the number of participants who improved their hip T-score at three months after treatment.
Time frame: 12 months
It refers to the number of participants who improved their lumbar spine T-score at three months after treatment.
Time frame: 12 months
It refers to the number of participants that present a hip T-score above -2.5 three months after treatment.
Time frame: 12 months
It refers to the number of participants that present a lumbar spine T-score greater than -2.5 three months after treatment.
Time frame: 12 months
It refers to the number of participants that present a hip T-score from -1 to -2.4 three months after treatment.
Time frame: 12 months
It refers to the number of participants that present a lumbar spine T-score from -1 to -2.4 three months after treatment.
Time frame: 12 months
It refers to the number of participants that present a hip T-score below -1 three months after treatment.
Time frame: 12 months
It refers to the number of participants that present a lumbar spine T-score below -1 three months after treatment.
Time frame: 12 months
Improvement in serum levels of 25-hydroxy vitamin D [25(OH)D] was considered when serum vitamin D levels increased concerning baseline levels.
Time frame: 12 months
Remission of hypovitaminosis D was considered when serum levels of 25-hydroxy vitamin D [25(OH)D] were above 29 pg/ml.
Time frame: 12 months
It refers to the number of participants who reached serum levels of vitamin D above 29 pg/ml after three months of treatment.
Time frame: 12 months
It refers to the number of participants who reached serum levels of vitamin D of 21 to 29 pg/ml after three months of treatment.
Time frame: 12 months
It refers to the number of participants who reached serum levels of vitamin D less than 20 pg/ml after three months of treatment.
Hospital Regional 1o de Octubre
Other
Vitamin D Improves Osteoporosis in Postmenopausal Women With Denosumab Failure
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05347082
Avitaminosis, Bone Diseases
Mexico City, Mexico
View Trial DetailsNCT05346419
Avitaminosis, Bone Diseases
Mexico City, Mexico
View Trial DetailsNCT02534714
Avitaminosis, Bone Diseases
Peoria, Illinois, United States
View Trial DetailsNCT01315366
Avitaminosis, Body Weight
Beirut, Lebanon
View Trial Details